Personalis (NASDAQ:PSNL) Reaches New 52-Week High – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) reached a new 52-week high during trading on Tuesday . The company traded as high as $11.18 and last traded at $11.1150, with a volume of 1817487 shares traded. The stock had previously closed at $9.99.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PSNL. Morgan Stanley raised their price objective on shares of Personalis from $5.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Guggenheim increased their target price on Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, HC Wainwright lifted their target price on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.29.

Personalis Stock Up 10.0%

The company has a market cap of $975.73 million, a P/E ratio of -12.43 and a beta of 1.92. The business has a 50-day moving average price of $7.98 and a two-hundred day moving average price of $6.41.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Insider Activity at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Personalis

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd lifted its stake in Personalis by 147.0% in the first quarter. XTX Topco Ltd now owns 82,666 shares of the company’s stock valued at $290,000 after acquiring an additional 49,197 shares during the last quarter. Howland Capital Management LLC raised its holdings in shares of Personalis by 7.7% in the 1st quarter. Howland Capital Management LLC now owns 282,808 shares of the company’s stock valued at $993,000 after purchasing an additional 20,200 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Personalis by 120.8% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 55,583 shares of the company’s stock valued at $195,000 after purchasing an additional 30,415 shares during the last quarter. Aberdeen Group plc lifted its stake in Personalis by 472.3% in the 1st quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after purchasing an additional 1,406,895 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in Personalis by 33.9% during the first quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock worth $236,000 after purchasing an additional 17,056 shares during the period. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.